In Brief: Bristol-Myers Squibb's Videx
Executive Summary
Bristol-Myers Squibb's Videx: ddI plus zidovudine combination shows 5% mortality rate in ZDV-experienced patients in ACTG 175 trial, the lowest death rate among the ZDV-experienced subgroup of the four arms in the study. Videx monotherapy patients who were ZDV-experienced had a 6% death rate during the trial; ZDV (Glaxo Wellcome's Retrovir) plus ddC (Roche's Hivid) showed a 9% mortality rate; and ZDV-experienced patients receiving ZDV alone experienced a 10% death rate in the ACTG study ("The Pink Sheet" Sept. 25, T&G-10)...